Thank afternoon. and us you, joining this thanks for everyone Patti, for
turn provide review update. business will I call reported Then, to I to over Mike the will we a results financial the earlier.
progress hyperhidrosis. life quality NASDAQ from suffer bromide significant as the drug of becoming in made a axillary about improve since and potential millions the company of sofpironium for Brickell’s to patients September. a primary enthusiastic listing on public the We remain of candidate who potentially
bromide of new why hyperhidrosis the best-in-class to me you story, an of we has overview let become potential and are who a Brickell’s for the the treatment. those For think sofpironium to market provide
underarm are U.S. medical the of sweating million of representing than people the is X.X% that suffer hyperhidrosis, approximately in to excessive greater condition to there XX which hyperhidrosis. most XX the approximately disease The ages the is In X% of socialized, beyond wellbeing, as is indicated disease hyperhidrosis prevalent axillary Hyperhidrosis and the and a XX in sweating, population. can referred regulation XX% what ages XX U.S. people their of to to million from negative from excessive alone, a have suffering is summary, younger body people temperature. about impact mental required have causes XX% that patients Over people people emotional U.S. affects and In XX. of on health. among XX
a side benefits with of novel, lead retrometabolically Our effects. agent, systemic designed intention topical which is while the reducing compound therapeutic local the bromide was sofpironium anticholinergic enhancing
rapid enhanced Sofpironium plasma a that fast Kaken at life bromide potentially over safety there To-date, clinical by short half partner and have conducted studies to been our XX with efficacy Japanese concentration. Brickell has profile included X,XXX favorable more or elimination, metabolic subjects. leading higher have deactivation a and
during March the the last Phase an announced were sofpironium both of and Research meeting bromide. announced American Kaken Two pivotal Japan year, from we the in XXst. oral Kaken Program development ago, of Late-Breaking selected at the annual Over results Brickell the in that presentation for significant weeks Dermatology study on Academy X progress
of first the While Phase subsequently in and concerns This pivotal released the sofpironium we coming has be due efficacy coronavirus, gel. expect be data will the from results canceled the bromide safety to conference about to the days. disclosure been X public study of
Under and to has are the Kaken, of to with a sofpironium certain in that study. results due agreement for positive new and other sales bromide drug develop in approval the sub-licensing China, manufacturing also payments Brickell. Asian based Japan rights announced of previously Kaken royalties Korea, there commercialize and submitted Kaken and application We this marketing milestone on countries.
with these patients Phase journal. of data by these we Xb prestigious peer positive peer encouraged of bromide the in primary axillary were in reviewed We academic study pleased In Journal by published that our X the Academy the of results of Dermatology. such with were American publication reviewed announced a hyperhidrosis Phase February, in results study with the are sofpironium and
axillary primary analysis These results give show and safety of to Kaken’s any sofpironium confidence the along sofpironium the pharmacokinetic evaluations results previous results, in Dermatology, bromide. in development with bromide January, us with gel of did accumulation. patients, Phase of presented to ages sofpironium the These Surgical XX Conference, concentration the findings at evidence the drug the XX% in with trial extension X advance from X long-term bromide continue hyperhidrosis. consistent major were pediatric investigational adults. metabolite to In & with we not The pharmacokinetics Aesthetic or
incidence Sofpironium high in bromide treatment events, is this of over had XX serious no since the safe pediatric no majority clinical adverse important the in severe weeks The relatively trial. was hyperhidrosis well-tolerated findings These emergent in and events. are were or pediatric the and of subjects of population. there adverse treatment,
look XX-week was safety, top-line results to X% forward to designed to pleased we earlier line This share Phase evaluate topically with our concentrations, study study two long-term bromide local and XX% sofpironium open-label the portion safety of completed of XXX also We’re applied in subjects efficacy gel. this soon. announcing hyperhidrosis. X tolerability of axillary that sofpironium and We multicenter year, of gel in these
licensor counterclaims SEC Company of mediation. and arbitration in Bodor an in against we filed XXXX, filed a licensor may alleged with our the have the announced against breach connection agreement. in that license Federal of participated releases our been filings the complaint subsequently October following and Court the you not and We those For of Labs months, few our last closely who in press through
that the with our resolving a of to Labs in February. Brickell cloud was balance Following this of felt allowed advance settlement We mediation, Bodor bromide and we stockholders continue without interest announced sofpironium litigation. in to dispute on the best
a X-point improvement from XX% the treated and FDA of follow-up. reported to XXX treatment, to with the the Phase called is X six Looking consist efficacy in sofpironium initiate applied sites. of scale the expected sweat of studies pivotal in to points double-blinded, development XX least to gel the each the baseline patients ahead, the gravimetric two-week end randomized, XX X across Phase the proportion production from outcome approximately are Subjects HDSM-Ax for baseline on next planned step agreed a studies topically of with in two of co-primary the United the The be trial. of end will The safety bromide patient multicenter, of The weeks treatment. for program is sofpironium vehicle-controlled, the States subjects end evaluating concentration. will identical and be efficacy achieving a to change at
achieved in significance both our Importantly, statistical Phase of concentration the Xb we on XX% at these dose-ranging endpoints study.
Phase X yet. haven’t guidance year, the move But, I of the start We progress. through we on forward to look our studies the two as reporting given on
over a now financial overview. to turn call Mike Mike? will the Carruthers for I
